GSK prepares for separation

Country

United Kingdom

GlaxoSmithKline plc plans to complete its previously announced restructuring – separating into a dedicated biopharma company and a new publicly-listed consumer healthcare business – over the next two years. The new biopharma business will focus on science related to the immune system, taking advantage of the company’s existing expertise in vaccines and immuno-oncology.